Cardiovascular

  • 25 February 2019

    Novartis exercises rights to Ionis’ CV drug TQJ230

    Swiss pharmaceutical giant Novartis has announced it has exercised the option to license its right to develop and commercialise TQJ230, a targeted cardiovascular (CV) therapy, from Akcea Therapeutics’ affiliate Ionis...

Close
Close
Close

Go Top